Literature DB >> 22012575

Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma.

Kaoru Okada1, Yoshiyuki Fujiwara, Yurika Nakamura, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Tsuyoshi Takahashi, Masaki Mori, Yuichiro Doki.   

Abstract

BACKGROUND: The aim of this study was to determine the expression of insulin-like growth factor-II messenger RNA (mRNA)-binding protein-3 (IMP-3) and its clinical significance in gastric cancers, as well the prognostic value of its expression in the peritoneal lavage fluid after surgery.
METHODS: IMP-3 expression was examined by immunohistochemistry in 96 primary gastric tumors. IMP-3 mRNA expression in peritoneal lavage fluid obtained at laparotomy was determine by real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR).
RESULTS: Positive staining for IMP-3 was observed in 74% (71/96) of the tumors. IMP-3 expression in gastric tumors correlated significantly with worst overall survival (OS) and recurrence-free survival. Multivariate analyses identified pathological N stage and IMP-3 expression as significant independent prognostic factors for disease-free survival. Eight (28%) of 36 peritoneal lavage samples were cytologically negative but positive for IMP-3 mRNA expression by RT-PCR. The OS of patients with IMP-3-positive peritoneal lavage was significantly worse than of those with negative expression.
CONCLUSIONS: IMP-3 expression in primary gastric tumors was an independent poor prognostic factor. IMP-3 mRNA expression in peritoneal lavage fluid was a predictor of recurrence after surgery in gastric cancer and a marker of poor prognosis.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012575     DOI: 10.1002/jso.22108

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

1.  IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status.

Authors:  Emanuel Adelino M Damasceno; Fabiana Pirani Carneiro; Albino Verçosa de Magalhães; Marcos de Vasconcelos Carneiro; Gustavo Henrique Soares Takano; Leonora Maciel de Sousa Vianna; Heinrich Bender Kohnert Seidler; Tercia Maria Mendes Lousa de Castro; Maria Imaculada Muniz-Junqueira; Rivadávio Fernandes Batista Amorim; Vânia Maria Moraes Ferreira; Andrea Barreto Motoyama
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-17       Impact factor: 4.553

2.  Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.

Authors:  Patrick Sven Plum; Dita Ulase; Elfriede Bollschweiler; Seung-Hun Chon; Felix Berlth; Thomas Zander; Hakan Alakus; Arnulf H Hölscher; Christiane J Bruns; Simon Schallenberg; Alexander Quaas; Heike Loeser
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-04       Impact factor: 4.553

3.  Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Li-Mian Er; Yong Li; Ming-Li Wu; Qun Zhao; Bi-Bo Tan; Xiao-Ling Wang; Shi-Jie Wang
Journal:  Oncol Lett       Date:  2017-02-14       Impact factor: 2.967

4.  Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.

Authors:  Johanna D Strehl; Josef Hoegel; Ines Hornicek; Arndt Hartmann; Marc-Oliver Riener
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

5.  Prognostic value of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer.

Authors:  Akihiro Takata; Yukinori Kurokawa; Yoshiyuki Fujiwara; Yurika Nakamura; Tsuyoshi Takahashi; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

6.  Expression of insulin-like growth factor-II mRNA-binding protein-3 as a marker for predicting clinical outcome in patients with esophageal squamous cell carcinoma.

Authors:  Akihiro Takata; Shuji Takiguchi; Kaoru Okada; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Masaki Mori; Yuichiro Doki
Journal:  Oncol Lett       Date:  2014-08-20       Impact factor: 2.967

7.  Insulin-Like Growth Factor II mRNA-Binding Protein 3 (IMP3) as a Useful Immunohistochemical Marker for the Diagnosis of Adenocarcinoma of Small Intestine.

Authors:  Seiichi Daikuhara; Takeshi Uehara; Kayoko Higuchi; Noriko Hosaka; Mai Iwaya; Yasuhiro Maruyama; Kazuyuki Matsuda; Norikazu Arakura; Eiji Tanaka; Hiroyoshi Ota
Journal:  Acta Histochem Cytochem       Date:  2015-12-18       Impact factor: 1.938

8.  Prognostic Significance of Molecular Analysis of Peritoneal Fluid for Patients with Gastric Cancer: A Meta-Analysis.

Authors:  Kai Deng; Hong Zhu; Mo Chen; Junchao Wu; Renwei Hu; Chengwei Tang
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

Review 9.  Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.

Authors:  Christos Vaklavas; Scott W Blume; William E Grizzle
Journal:  Front Oncol       Date:  2017-07-26       Impact factor: 6.244

10.  Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma.

Authors:  Lijuan Lin; Jinhui Zhang; Yan Wang; Weiei Ju; Yibing Ma; Lina Li; Litian Chen
Journal:  Oncol Lett       Date:  2013-07-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.